What FLT3 inhibitor holds the greatest promise?

Publication date: Available online 20 September 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Richard M. StoneAbstractDetermining which FLT3 inhibitor holds the greatest promise is a difficult task, as the drugs vary according to potency, specificity, protein-binding, drug interactions, and side effect profile. The best choice depends on when in the course of the disease the inhibitor will be used. Moreover, as the results of ongoing trials become available, newer agents could supplant former ‘best’ drugs. This paper reviews FLT3 inhibitors in combination with chemotherapy early in the disease in FLT3 mutant patients, as single agents or in combination in advanced disease, or in the post-transplant setting to provide separate answers to the main question.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research